Anecortave acetate
- Generic Name
- Anecortave acetate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30O5
- CAS Number
- 7753-60-8
- Unique Ingredient Identifier
- Y0PC411K4T
- Background
Anecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group. As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.
- Indication
Investigated for use/treatment in glaucoma and macular degeneration.
- Associated Conditions
- -
- Associated Therapies
- -
Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Registration Number
- NCT00211471
- Locations
- 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States
Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-10-24
- Lead Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT00211315
- Locations
- 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
- Conditions
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2012-11-29
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT00058994
- Locations
- 🇺🇸
South America, Fort Worth, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.